Drug Profile
CNF 201
Alternative Names: CNF201Latest Information Update: 08 Apr 2010
Price :
$50
*
At a glance
- Originator Biogen Idec
- Class Antineoplastics
- Mechanism of Action ERBB 2 receptor antagonists; Heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 08 Apr 2010 Discontinued - Preclinical for Breast cancer in USA (unspecified route)
- 03 May 2006 Conforma Therapeutics has been acquired and merged into Biogen Idec
- 21 Dec 2001 Preclinical development for Breast cancer in USA (Unknown route)